Literature DB >> 10748416

Clinical involvement and protein expression in individuals with the FMR1 premutation.

F Tassone1, R J Hagerman, A K Taylor, J B Mills, S W Harris, L W Gane, P J Hagerman.   

Abstract

Most individuals with the fragile X premutation are clinically unaffected; however, some show clinical manifestations, including learning difficulties, emotional problems, or even mental retardation. The basis of clinical involvement in these individuals is unknown. Premutation alleles are reportedly associated with normal levels of mRNA and protein (FMRP). To examine this issue in more detail, we studied six individuals with a premutation. We are reporting these cases to demonstrate a spectrum of phenotypic involvement which can be seen clinically. These cases include one individual with the premutation who has no evidence of FMR1 gene dysfunction but has mental retardation from other causes. Other cases presented here show varying degrees of FMR1 gene dysfunction as assessed by FMRP and FMR1 mRNA levels and various clinical features of fragile X. In two cases we observed a significant reduction in FMRP expression and an elevated FMR1 mRNA expression level associated with moderate cognitive deficit. Thus, the utilization of FMRP measures can be helpful in understanding for which premutation patients clinical involvement is caused by dysfunction of the FMR1 gene. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748416     DOI: 10.1002/(sici)1096-8628(20000313)91:2<144::aid-ajmg14>3.0.co;2-v

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  89 in total

1.  Trisomic pregnancy and intermediate CGG repeat length at the FMR1 locus.

Authors:  J Kline; A Kinney; S Brown; B Levin; K Oppenheimer; D Warburton
Journal:  Hum Reprod       Date:  2012-04-06       Impact factor: 6.918

Review 2.  RNA-mediated neurodegeneration in repeat expansion disorders.

Authors:  Peter K Todd; Henry L Paulson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

3.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

4.  Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.

Authors:  Michael R Hunsaker; Gloria Arque; Robert F Berman; Rob Willemsen; Renate K Hukema
Journal:  Results Probl Cell Differ       Date:  2012

Review 5.  Insights into brain development from neurogenetic syndromes: evidence from fragile X syndrome, Williams syndrome, Turner syndrome and velocardiofacial syndrome.

Authors:  E Walter; P K Mazaika; A L Reiss
Journal:  Neuroscience       Date:  2009-04-17       Impact factor: 3.590

Review 6.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

7.  Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation.

Authors:  Michael R Hunsaker; Naomi J Goodrich-Hunsaker; Rob Willemsen; Robert F Berman
Journal:  Behav Brain Res       Date:  2010-05-15       Impact factor: 3.332

8.  Altered neural activity of magnitude estimation processing in adults with the fragile X premutation.

Authors:  So-Yeon Kim; Ryu-ichiro Hashimoto; Flora Tassone; Tony J Simon; Susan M Rivera
Journal:  J Psychiatr Res       Date:  2013-09-02       Impact factor: 4.791

9.  FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.

Authors:  Karla L Bretherick; Margo R Fluker; Wendy P Robinson
Journal:  Hum Genet       Date:  2005-06-02       Impact factor: 4.132

10.  Co-occurring diagnoses among FMR1 premutation allele carriers.

Authors:  J E Hunter; J K Rohr; S L Sherman
Journal:  Clin Genet       Date:  2010-01-06       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.